AMBA 

AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer^[1].

AMBA (0.001-1000 nmol/L; 60 min) exhibits high specificity and nanomolar affinity for human GRPR receptors, with an IC₅₀ of 0.82 nmol/L and a K_i of 0.65nmol/L^[1].
AMBA (6.66 × 10^-4 μmol (1 μg); 10 min) can be efficiently radiolabeled with ¹¹¹In, achieving a radiolabeling efficiency of 95.43% under the tested conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

¹¹¹In-AMBA (0.37 MBq-12.2 MBq/4 μg; i.v.; single dose) achieves peak tumor uptake of 3.87 ± 0.65% ID/g at 8 hours post-injection in PC-3 prostate tumor-bearing SCID mice, with a maximum tumor/muscle ratio of 11.79, demonstrating effective targeting of GRPR-expressing tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1502.70

C₆₈H₉₉N₁₉O₁₈S

721937-56-0

{DOTA}-Gly-{PAB}-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2

{DOTA}-G-{PAB}-QWAVGHLM-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ho CL, et al. Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice. J Biomed Biotechnol. 2011;2011:101497.  [Content Brief]